Sana Biotechnology
SANA
154 hedge funds and large institutions have $1.46B invested in Sana Biotechnology in 2024 Q1 according to their latest regulatory filings, with 38 funds opening new positions, 46 increasing their positions, 40 reducing their positions, and 15 closing their positions.
188% more capital invested
Capital invested by funds: $508M → $1.46B (+$955M)
153% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 15
61% more call options, than puts
Call options by funds: $3.96M | Put options by funds: $2.47M
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
17% more funds holding
Funds holding: 132 → 154 (+22)
15% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 40
3.21% more ownership
Funds ownership: 63.17% → 66.38% (+3.2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$47.1M |
| 2 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$36M |
| 3 |
Capital World Investors
Los Angeles,
California
|
+$29.3M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$17.7M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$13.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$16.4M |
| 2 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$9.05M |
| 3 |
SCM
Suvretta Capital Management
New York
|
-$6.55M |
| 4 |
Massachusetts Financial Services
Boston,
Massachusetts
|
-$6.1M |
| 5 |
Barclays
London,
United Kingdom
|
-$1.76M |
SANA Hedge Fund Activity: Q1 2024 in Review
154 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Sana Biotechnology (SANA) for Q1 2024, worth a combined $1.46B — up 188% from $508M a quarter earlier.
Buyers outnumbered sellers: 38 funds opened new SANA positions and 15 closed out — a net gain of 23 holders — while 46 added to existing stakes and 40 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $47.1M. The largest seller was Millennium Management, cutting an estimated $16.4M.
- 154 institutional investors held Sana Biotechnology (SANA) as of Q1 2024, up from 132 in Q4 2023.
- Funds reported $1.46B of Sana Biotechnology stock for Q1 2024, up 188% quarter-over-quarter.
- 38 funds opened new Sana Biotechnology positions in Q1 2024 and 15 closed out, a net change of +23 holders.
- The largest Sana Biotechnology buyer in Q1 2024 was Fidelity Investments, an estimated $47.1M added.
- The largest Sana Biotechnology seller in Q1 2024 was Millennium Management, an estimated $16.4M sold.
Based on aggregated 13F filings for Q1 2024.